Sanofi-Aventis and Regulus, Inc. have entered into a global strategic alliance to discover, develop, and commercialize microRNA therapeutics. The alliance will initially focus on fibrosis treatments. MicroRNAs (micro-RiboNucleic Acid) are a new class of small non-coding RNAs that regulate gene expression by interfering with the stability of target messenger RNA transcripts. The two companies will collaborate on microRNA drug discovery and preclinical development for as many as four microRNA ...